Patent: 9,844,582
✉ Email this page to a colleague
Summary for Patent: 9,844,582
Title: | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
Abstract: | The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer. |
Inventor(s): | Wittrup; Karl Dane (Chestnut Hill, MA), Kwan; Byron Hua (Boston, MA), Gai; Shuning (Cambridge, MA) |
Assignee: | Massachusetts Institute of Technology (Cambridge, MA) |
Application Number: | 14/402,889 |
Patent Claims: | see list of patent claims |
Details for Patent 9,844,582
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-05-22 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-05-22 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-05-22 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2032-05-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |